Spark Therapeutics Proposes Value-Based Reimbursement, Installment Plans for Luxturna

Drug Industry Daily
Amid controversy over the high cost of its newly approved gene therapy Luxturna — $850,000 before discounts — Spark Therapeutics announced a series of initiatives to improve patient access to the drug, including outcomes-based arrangements with Harvard Pilgrim and Express Scripts.

To View This Article:


Subscribe To Drug Industry Daily